Stockreport

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology [Yahoo! Finance]

Rigel Pharmaceuticals, Inc.  (RIGL) 
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.rigel.com
PDF Rigel advances its strategic collaborations to further evaluate olutasidenib with the activation of a fifth study with MD Anderson and enrollment of the first patient i [Read more]